Supplement | HBS Case Collection | January 2014

Fred Khosravi and AccessClosure (C)

by Richard Hamermesh and Lauren Barley

Abstract

On September 11, 2013, the three-judge panel of the U.S. Court of Appeals for the Federal Circuit denied St. Jude's request to rehear an appeal on the "double patenting" ruling for the '439 patent. Further, it removed the injunction threat that was hanging over the company. The future looked bright for AccessClosure as 2013 drew to a close. The company expected 2014 revenues of more than $100 million with a gross margin of greater than 70%. It was also anticipating FDA approval on a significant product improvement within the next several months.

Keywords: medical devices; vascular closure device; patent litigation; Patenting; Biotechnology Industry; Biomedical Research; biotechnology; biotech; Technological Innovation; Patents; Health Care and Treatment; Biotechnology Industry; United States;

Citation:

Hamermesh, Richard, and Lauren Barley. "Fred Khosravi and AccessClosure (C)." Harvard Business School Supplement 814-074, January 2014.